IgGenix is a privately held antibody discovery and development company taking a revolutionary approach to directly address severe allergies. Through our proprietary SEQ SIFTER discovery platform, developed from the foundational research of co-founders Stephen Quake, Kari Nadeau and Derek Croote of Stanford University, IgGenix isolates and re-engineers fully human, high-affinity, allergen-specific IgG antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant allergens and their most immunodominant epitopes across the patient population, we intend to treat allergic pediatric and adult patients alike across severe food and environmental allergies.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/06/23	$40,000,000	Series B	Alexandria Venture Investments AllerFund Eli Lilly and Company Khosla Ventures Sean Parker	undisclosed